Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial

BACKGROUND: Randomised placebo-controlled trials have shown that daily oral pre-exposure prophylaxis (PrEP) with tenofovir–emtricitabine reduces the risk of HIV infection. However, this benefit could be counteracted by risk compensation in users of PrEP. We did the PROUD study to assess this effect....

Descripción completa

Detalles Bibliográficos
Autores principales: McCormack, Sheena, Dunn, David T, Desai, Monica, Dolling, David I, Gafos, Mitzy, Gilson, Richard, Sullivan, Ann K, Clarke, Amanda, Reeves, Iain, Schembri, Gabriel, Mackie, Nicola, Bowman, Christine, Lacey, Charles J, Apea, Vanessa, Brady, Michael, Fox, Julie, Taylor, Stephen, Antonucci, Simone, Khoo, Saye H, Rooney, James, Nardone, Anthony, Fisher, Martin, McOwan, Alan, Phillips, Andrew N, Johnson, Anne M, Gazzard, Brian, Gill, Owen N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4700047/
https://www.ncbi.nlm.nih.gov/pubmed/26364263
http://dx.doi.org/10.1016/S0140-6736(15)00056-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4700047/
https://www.ncbi.nlm.nih.gov/pubmed/26364263
http://dx.doi.org/10.1016/S0140-6736(15)00056-2

Ejemplares similares